LFMDLifeMD, Inc.
The schedule
- Thu15Oct
Assessment of FDA stance on compounded GLP-1s and market share dynamics.
- Wed3Feb
Q3 results focusing on customer acquisition cost (CAC) stabilization and gross margins.
- Wed5May
Year-end results and forward guidance for FY27 profitability.
- Wed4Aug
First quarter results to validate FY27 operational targets.
Past
- Wed5Aug
Actual outcome: Bear · $3.46 at outcome
LifeMD reported Q2 revenue of $47.3 million, which fell on the lower end of guidance and lagged estimates, alongside an adjusted EBITDA loss of $3.5 million. The stock declined as profitability was pressured by elevated customer acquisition costs and lower introductory pricing for its branded GLP-1 care, raising concerns about the margins of its weight management vertical.
Q2 earnings evaluating profitability progress and GLP-1 vertical growth.
- Wed6May
Actual outcome: Bear · $4.26 at outcome
LifeMD reported Q1 2026 results with a loss of $0.20 per share, which missed the Zacks consensus estimate of a $0.14 loss and marked a sharp decline from the $0.01 per share profit reported a year ago. Although revenue of $50.2 million exceeded guidance and gross margins improved to 88%, the persistent lack of bottom-line profitability and an adjusted EBITDA loss of $4.5 million overshadowed the top-line beat, driving the stock down 19.2%.
LifeMD reported Q1 2026 results with a loss of $0.20 per share, which missed the Zacks consensus estimate of a $0.14 loss and marked a sharp decline from the $0.01 per share profit reported a year ago. Although revenue of $50.2 million exceeded guidance and gross margins improved to 88%, the persistent lack of bottom-line profitability and an adjusted EBITDA loss of $4.5 million overshadowed the top-line beat, driving the stock down 19.2%.
- Mon9Mar
Actual outcome: Bull · $3.93 at outcome
LifeMD reported Q4 2025 results with revenue increasing 4% to $46.9 million and adjusted EBITDA surging 348% to $4.8 million, while EPS met expectations. The stock rallied significantly, driven by the strong profitability growth, the strategic divestment of WorkSimpli to become a pure-play telehealth provider, and optimism surrounding the launch of the Wegovy pill to expand its GLP-1 weight-loss vertical.
LifeMD reported Q4 2025 results with revenue increasing 4% to $46.9 million and adjusted EBITDA surging 348% to $4.8 million, while EPS met expectations. The stock rallied significantly, driven by the strong profitability growth, the strategic divestment of WorkSimpli to become a pure-play telehealth provider, and optimism surrounding the launch of the Wegovy pill to expand its GLP-1 weight-loss vertical.